Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.
The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform.
But Noom is the latest in a string of digital health companies to offer compounded versions of the medications as a cheaper alternative for consumers while demand for weight loss and diabetes drugs spikes. Hims & Hers and Sesame have launched similar programs in recent months — and the market for low-cost options has grown more competitive.
“Our position is that more supply, especially at a reasonable price, is needed right now, not less,” Noom CEO Geoff Cook told CNBC in an interview.
Wegovy and Ozempic belong to a highly popular class of medications called GLP-1s, which mimic certain gut hormones to tamp down a patient’s appetite and regulate their blood sugar. The compounded versions are custom-made alternatives to the brand drugs, and they can be produced when brand-name treatments are in shortage.
Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Wegovy and Ozempic both cost roughly $1,000 per month before insurance. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Spiking demand can also make it difficult for many patients to find the branded treatments.
Cook said consumers will pay $149 for their first month in Noom’s program and $279 for the following months as the dose of their medication increases.
The U.S. Food and Drug Administration does not review the safety and efficacy of compounded products, and the agency has urged consumers to take the approved, branded GLP-1 medications when they are available. However, the FDA does inspect some outsourcing facilities that compound drugs, according to its website.
Noom said it is working with an FDA-regulated 503B compounding pharmacy to provide its medication for its new program, which is called Noom GLP-1 RX.
“The drug manufacturer we’re working with generates 20 generic medications, epinephrine being one of them — a lifesaving medication that’s available in hospitals all across the United States,” Dr. Adonis Saremi, chief medical officer of Noom, told CNBC in an interview. “So we’re really confident and happy with our vetting process.”
The company said ithas also introduced a way for participants to taper off the compounded treatment if they would like to stop taking it. GLP-1s are intended for long-term use, which means some patients may end up taking them indefinitely.
Cook said Noom has seen both anecdotal and real-world evidence that patients are able to maintain weight loss after they stop taking the drugs. Six out of seven patients are off GLP-1s by the two-year mark anyway, he said.
“It’s prescribed by the doctor, the person takes their medicine, they lose weight, but then life happens,” Cook said. “They eventually stop taking the medication, or their insurance stops covering it, they’ll change a job [so] it’s no longer covered.”
Cook said not everyone will be able to taper off the medication, so some people will likely end up taking it indefinitely. The company will provide a free year of Noom or “substantial medication discounts” to anyone who regains the weight within 18 months after following its program for a year, it said in a release.
Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website. Noom said one of its contracted, obesity-trained doctors will review the intake form and decide if the compounded medication is appropriate for that patient. If so, the drugs will arrive at their door within a week, Noom said.
Participants will learn how to inject their medication, and they can use a chat feature to talk one-on-one with a coach and their Noom clinician, the company said. They’ll also have access to a range of psychology-based programming and tools to help keep them from losing muscle mass, such as features for tracking protein intake and engaging in resistance training, Noom said.
And if users decide they are ready to move off the medication, they can chat with their clinician or tap “initiate taper” in their settings, Noom said.
“I think there’s a lot of folks who don’t want to be on a medication for the rest of their lives, and in any event, people aren’t doing that in the real world,” Cook said. “Our goal is just not to sell more medications. It’s to drive sustained weight loss outcomes.”
Inside Horizon Quantum’s office in Singapore on Dec. 3, 2025. The software firm claimed it is the first private company to deploy a commercial quantum computer in the city-state.
Sha Ying | CNBC International
Singapore-based software firm Horizon Quantum on Wednesday said it has become the first private company to run a quantum computer for commercial use in the city-state, marking a milestone ahead of its plans to list in the U.S.
The start-up, founded in 2018 by quantum researcher Joe Fitzsimons, said the machine is now fully operational. It integrates components from quantum computing suppliers, including Maybell Quantum, Quantum Machines and Rigetti Computing.
According to Horizon Quantum, the new computer also makes it the first pure-play quantum software firm to own its own quantum computer — an integration it hopes will help advance the promising technology.
“Our focus is on helping developers to start harnessing quantum computers to do real-world work,” Fitzsimons, the CEO, told CNBC. “How do we take full advantage of these systems? How do we program them?”
Horizon Quantum builds the software tools and infrastructure needed to power applications for quantum computing systems.
“Although we’re very much focused on the software side, it’s really important to understand how the stack works down to the physical level … that’s the reason we have a test bed now,” Fitzsimons said.
Quantum race
Horizon Quantum hopes to use its new hardware to accelerate the development of real-world quantum applications across industries, from pharmaceuticals to finance.
Quantum systems aim to tackle problems too complex for traditional machines by leveraging principles of quantum mechanics.
For example, designing new drugs, which requires simulating molecular interactions, or running millions of scenarios to assess portfolio risk, can be slow and computationally costly for conventional machines. Quantum computing is expected to provide faster, more accurate models to tackle these problems.
A top executive at Google working on quantum computers told CNBC in March that he believes the technology is only five years away from running practical applications.
Still, today’s quantum systems remain in the nascent stages of development and pose many engineering and programming challenges.
Investment in the space has been rising, however, as major tech companies report technological breakthroughs. Alphabet, Microsoft, Amazon and IBM, along with the U.S. government, are already pouring millions into quantum computing.
Investor attention also received a bump in June after Nvidia chief executive Jensen Huang offered upbeat remarks, saying quantum computing is nearing an “inflection point” and that practical uses may arrive sooner than he had expected.
Nasdaq listing
Horizon Quantum’s announcement comes ahead of a merger with dMY Squared Technology Group Inc., a special purpose acquisition company. The deal, agreed upon in September, aims to take Horizon public on the Nasdaq under the ticker “HQ.”
The software firm said in September that the transaction valued the company at around $503 million and was expected to close in the first quarter of 2026.
The launch of its quantum computer also helps cement Singapore’s ambition to be a regional quantum computing hub. The city-state has invested heavily in the technology for years, setting up its first quantum research center in 2007.
Before Horizon Quantum’s system came online, Singapore reportedly had one quantum computer, used primarily for research purposes. Meanwhile, U.S.-based firm Quantinuum plans to deploy another commercial system in 2026.
Singapore’s National Quantum Strategy, unveiled in May 2024, committed 300 million Singapore dollars over five years to expand the sector, with a significant portion directed toward building local quantum computer processors.
In May 2024, the National Quantum Strategy (NQS), Singapore’s national quantum initiative, pledged around S$300 million over five years to strengthen development in the sector, with a significant portion directed toward building local quantum computer processors.
The moon vacuum, which was unveiled on Wednesday by Blue Origin at Amazon‘s re:Invent 2025 conference in Las Vegas, was built using critical technology from startup Istari Digital.
“So what it does is sucks up moon dust and it extracts the heat from it so it can be used as an energy source, like turning moon dust into a battery,” Istari CEO Will Roper told CNBC’s Morgan Brennan.
Spacecraft carrying out missions on the lunar surface are typically constrained by lunar night, the two-week period every 28 days during which the moon is cast in darkness and temperatures experience extreme drops, crippling hardware and rendering it useless unless a strong, long-lasting power source is present.
“Kind of like vacuuming at home, but creating your own electricity while you do it,” he added.
The battery was completely designed by AI, said Roper, who was assistant secretary of the Air Force under President Donald Trump‘s first term and is known for transforming the acquisition process at both the Air Force and, at the time, the newly created Space Force.
Read more CNBC tech news
A major part of the breakthrough in Istari’s technology is the way in which it handles and limits AI hallucinations.
Roper said the platform takes all the requirements a part needs and creates guardrails or a “fence around the playground” that the AI can’t leave while coming up with designs.
“Within that playground, AI can generate to its heart’s content,” he said.
“In the case of Blue Origin’s moon battery, [it] doesn’t tell you the design was a good one, but it tells us that all of the requirements were met, the standards were met, things like that that you got to check before you go operational,” he added.
Istari is backed by former Google CEO Eric Schmidt and already works with the U.S. government, including as a prime contractor with Lockheed Martin on the experimental x-56A unmanned aircraft.
Watch the full interview above and go deeper into the business of the stars with the Manifest Space podcast.
Nvidia CEO Jensen Huang said he met with President Donald Trump on Wednesday and that the two men discussed chip export restrictions, as lawmakers consider a proposal to limit exports of advanced artificial intelligence chips to nations like China.
“I’ve said it repeatedly that we support export controls, and that we should ensure that American companies have the best and the most and first,” Huang told reporters on Capitol Hill.
Lawmakers were considering including the Guaranteeing Access and Innovation for National Artificial Intelligence Act in a major defense package, known as the National Defense Authorization Act. The GAIN AI Act would require chipmakers like Nvidia and Advanced Micro Devices to give U.S. companies first pick on their AI chips before selling them in countries like China.
The proposal isn’t expected to be part of the NDAA, Bloomberg reported, citing a person familiar with the matter.
Huang said it was “wise” that the proposal is being left out of the annual defense policy bill.
“The GAIN AI Act is even more detrimental to the United States than the AI Diffusion Act,” Huang said.
Nvidia’s CEO also criticized the idea of establishing a patchwork of state laws regulating AI. The notion of state-by-state regulation has generated pushback from tech companies and spurred the creation of a super PAC called “Leading the Future,” which is backed by the AI industry.
“State-by-state AI regulation would drag this industry into a halt and it would create a national security concern, as we need to make sure that the United States advances AI technology as quickly as possible,” Huang said. “A federal AI regulation is the wisest.”
Trump last month urged legislators to include a provision in the NDAA that would preempt state AI laws in favor of “one federal standard.”
But House Majority Leader Steve Scalise (R-LA) told CNBC’s Emily Wilkins on Tuesday the provision won’t make it into the bill, citing a lack of sufficient support. He and other lawmakers will continue to look for ways to establish a national standard on AI, Scalise added.